Automate Your Wheel Strategy on RVTY
With Tiblio's Option Bot, you can configure your own wheel strategy including RVTY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RVTY
- Rev/Share 23.809
- Book/Share 64.287
- PB 1.4132
- Debt/Equity 0.4466
- CurrentRatio 3.3286
- ROIC 0.0287
- MktCap 10708489500.0
- FreeCF/Share 4.3297
- PFCF 21.0421
- PE 37.4419
- Debt/Assets 0.273
- DivYield 0.0031
- ROE 0.0371
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RVTY | UBS | Neutral | Buy | -- | $115 | May 1, 2025 |
| Downgrade | RVTY | Bernstein | Outperform | Market Perform | -- | $130 | Jan. 10, 2025 |
| Upgrade | RVTY | BofA Securities | Neutral | Buy | -- | $138 | Dec. 13, 2024 |
| Upgrade | RVTY | Barclays | Equal Weight | Overweight | $125 | $140 | Oct. 15, 2024 |
| Initiation | RVTY | Wells Fargo | -- | Equal Weight | -- | $130 | Aug. 28, 2024 |
News
Revvity Q2: Headwinds From China And Customers, Buy On Weakness
Published: July 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc.'s focus on high-growth markets like cell and gene therapies and precision medicine positions it for long-term expansion despite near-term challenges. The recent divestiture streamlines Revvity's portfolio, allowing greater investment in specialized diagnostics and software, which are expected to drive future growth. While facing weak academic/government demand and China headwinds, Revvity maintains a strong capital structure and margin expansion potential through cost optimization.
Read More
Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook
Published: July 28, 2025 by: Investopedia
Sentiment: Negative
Revvity (RVTY) was one of the worst-performing stocks in the S&P 500 Monday after the medical device maker said it anticipated a "meaningful pullback" in its immunodiagnostics business in China.
Read More
Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More
Published: July 28, 2025 by: Investopedia
Sentiment: Positive
U.S. equities were mhigher at midday after President Donald Trump and European Commission President Ursula von der Leyen announced a new trade agreement between the U.S. and the European Union. The Dow Jones Industrial Average, Nasdaq, and S&P 500 all rose.
Read More
Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript
Published: July 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc. (NYSE:RVTY ) Q2 2025 Earnings Conference Call July 28, 2025 8:00 AM ET Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad R. Singh - CEO, President & Director Stephen Barr Willoughby - Senior VP of Investor Relations & Head of ESG Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Daniel Louis Leonard - UBS Investment Bank, Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Luke England Sergott - Barclays Bank PLC, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division …
Read More
RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.
Read More
Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Why Revvity (RVTY) is Poised to Beat Earnings Estimates Again
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
Read More
Wall Street's Insights Into Key Metrics Ahead of Revvity (RVTY) Q2 Earnings
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Revvity (RVTY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Read More
Revvity (RVTY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requi.
Read More
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
Read More
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 in.
Read More
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Negative
Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the company maintained full-year guidance. While I rate Revvity a buy, it faces some structural challenges longer-term.
Read More
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Read More
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Published: April 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and …
Read More
Revvity beats quarterly estimates on steady demand for medical equipment
Published: April 28, 2025 by: Reuters
Sentiment: Positive
Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for drug research.
Read More
Why Revvity (RVTY) Could Beat Earnings Estimates Again
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Read More
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
Read More
About Revvity, Inc. (RVTY)
- IPO Date 1965-07-06
- Website https://www.perkinelmer.com
- Industry Medical - Diagnostics & Research
- CEO Prahlad R. Singh
- Employees 11000